Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.04M Buy
4,146
+44
+1% +$9.47K 0.47% 62
2026
Q1
$892K Buy
4,102
+1
+0% +$222 0.46% 67
2025
Q4
$937K Buy
4,101
+26
+0.6% +$5.92K 0.48% 61
2025
Q3
$944K Buy
4,075
+107
+3% +$21.8K 0.5% 55
2025
Q2
$737K Sell
3,968
-58
-1% -$10.8K 0.42% 66
2025
Q1
$844K Buy
4,026
+1
+0% +$194 0.51% 59
2024
Q4
$715K Buy
4,025
+1,772
+79% +$326K 0.42% 70
2024
Q3
$445K Buy
+2,253
New +$420K 0.27% 90

Other funds holding ABBV

Tudor Financial's ABBV Position: Q2 2026 in Review

Tudor Financial increased its AbbVie (ABBV) stake by 1.1% in Q2 2026, buying an estimated $9.47K and bringing the position to 4,146 shares worth $1.04M. The position accounts for 0.47% of the portfolio, ranked #62.

Tudor Financial first reported a position in ABBV in Q3 2024 and has held it in 8 quarters since. 4,222 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Tudor Financial held 4,146 shares of AbbVie worth $1.04M as of Q2 2026.
  • Tudor Financial bought 44 AbbVie shares in Q2 2026, an estimated $9.47K.
  • AbbVie made up 0.47% of Tudor Financial's portfolio in Q2 2026, its #62 holding.
  • Tudor Financial first reported a position in AbbVie in Q3 2024 and has held it in 8 quarters since.
  • 4,222 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Tudor Financial's 13F filing for Q2 2026, filed 6 Aug 2026.